Efficacy of prolonged intermittent therapy with combined 5-fluorouracil and methyl-ccnu following resection for carcinoma of the large bowel. A veterans administration surgical oncology group report

Higgins, George A.; Amadeo, Jose H.; McElhinney, James; McCaughan, Joseph J.; Keehn, Robert J.

doi:10.1002/1097-0142(19840101)53:1<1::aid-cncr2820530102>3.0.co;2-l

Cited by 94 publications

(10 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Older trials of adjuvant chemotherapy using fluorouracil alone or combined with semustine, failed to show a significant improvement in either overall or disease-free survival for patients receiving treatment compared with concurrently randomized control patients receiving no adjuvant therapy [85][86][87][88].…”

Section: Overall Treatment Strategymentioning

confidence: 99%

Colon cancer

Labianca

Beretta

Gatta

et al. 2004

Critical Reviews in Oncology/Hematology

View full text Add to dashboard Cite

Colon cancer is one of the leading tumours in the world and is considered among the big killers, together with lung, prostate and breast cancer. In the recent years very important advances occurred in the field of treatment of this frequent disease: adjuvant chemotherapy was demonstrated to be effective, chiefly in stage III patients, and surgery was optimized in order to achieve the best results with a low morbidity. Several new target-oriented drugs are under evaluation and some of them (cetuximab and bevacizumab) have already exhibited a good activity/efficacy, mainly in combination with chemotherapy. The development of updated recommendations for the best management of these patients is crucial in order to obtain the best results, not only in clinical research but also in everyday practice. This report summarizes the most important achievements in this field and provides the readers useful suggestions for their professional practice.

show abstract

Section: Overall Treatment Strategymentioning

confidence: 99%

Colon cancer

Labianca

Beretta

Gatta

et al. 2004

Critical Reviews in Oncology/Hematology

View full text Add to dashboard Cite

show abstract

“…After a median 4-year follow-up, a significant (P<0.03) survival benefit was reported for treated patients. However, subsequent randomized trials of these agents by the Veterans Administration Surgical Oncology Study Group and the Eastern Cooperative Oncology Group showed no survival advantage for this adjuvant therapy compared with surgery alone [22,23].…”

Section: Combination Chemotherapymentioning

confidence: 99%

Adjuvant and preoperative chemotherapy for gastric cancer

Yao

Ajani

2002

Curr Oncol Rep

View full text Add to dashboard Cite

Gastric cancer is the second most frequently diagnosed malignancy worldwide, and the risk of relapse remains high in the majority of patients undergoing resection. Attempts to reduce this risk and prolong survival have led to numerous adjuvant chemotherapy trials that either had no benefit for patients or occasionally had controversial results. The recently reported Intergroup 0116 trial shows conclusive evidence of survival benefit for patients treated with postoperative chemoradiotherapy. In this Intergroup trial, which involves over 600 patients, a regimen of postoperative chemotherapy plus chemoradiotherapy was shown to prolong overall and disease-free survival in gastric cancer patients with stage IB through IV disease following a curative (R0) resection. This approach should be considered the standard of care in patients with gastric cancer who have undergone curative resection. Preoperative chemotherapy shows promise in downstaging tumors and increasing the rate of curative resection, but randomized trials are needed to assess survival benefits. Efforts to combine existing treatment modalities and new agents with novel mechanisms of action hold promise for the future.

show abstract

“…The Veterans Administration Surgical Oncology Group compared 5-FU and methyl-CCNU to observation and failed to demonstrate any treatment advantage [4]. Results with bacille Calmette-Guérin (BCG) in animal tumor model systems prompted a trial by the Gastrointestinal Tumor Study Group (GITSG), in which 621 patients with Dukes' stage B2 and C disease were randomized postoperatively to observation or therapy with methyl-CCNU and 5-FU, BCG, or a combination of BCG and chemotherapy.…”

Section: Clinical Trials Of Adjuvant Chemotherapymentioning

confidence: 99%

Adjuvant chemotherapy for colon cancer

Kumar

Goldberg

2001

Curr Oncol Rep

View full text Add to dashboard Cite

Colon cancer remains the third most common cancer, and cause of cancer-related death in the United States. Greater public awareness and acceptance of screening programs have contributed significantly to increasingly earlier detection of colon cancer and decreased mortality. Advances made in the understanding of this disease, both in terms of its clinical behavior and molecular pathogenesis, have translated into major improvements in its therapy. Several large randomized trials during the last two decades have helped the oncology community forge a successful multi-modality treatment strategy against colon cancer. These studies have defined the role of adjuvant therapy for colon cancer after curative surgery. Despite all the advances, a large number of patients continue to succumb to this disease, and the search for better therapies is still necessary. In this article, we discuss the evolution and the current state of adjuvant chemotherapy in colon cancer and briefly review new developments.

show abstract

Efficacy of prolonged intermittent therapy with combined 5-fluorouracil and methyl-ccnu following resection for carcinoma of the large bowel. A veterans administration surgical oncology group report

Cited by 94 publications

References 9 publications

Colon cancer

Colon cancer

Adjuvant and preoperative chemotherapy for gastric cancer

Adjuvant chemotherapy for colon cancer

Contact Info

Product

Resources

About